Hospitalization causes due to iron overload in beta-Thalassemia in Gorgan, Iran

Objective: To evaluate causes of hospitalization (due to complications of iron overload and other causes) in beta-Thalassemic patients. Methodology: This study was performed on 244 patients with major beta-Thalassemia admitted in Taleghani hospital of Gorgan between 2000 and 2007. Causes of hospitalization (due to complications of iron overload and other causes) were evaluated. Data were analyzed with SPSS software. Results: The most common causes of hospitalization due to iron overload were diabetes mellitus (31.6%) and heart failure (16.4%). The most common clinical findings were weakness and fatigue. Conclusion: We perceive increased frequency of diabetes mellitus in this center compared to other studies in Iran and abroad. Therefore glucose tolerance test and genotypic research for IVS II nt 745 are recommended in Thalassemic patient in this area

Prevalence and intensity of depression in mothers of children with beta-thalassemia major in Talghani Hospital of Gorgan, Iran

Background: Thalassemia is a chronic disease that it leads to psychological and social problems for parents. Mothers are at markedly increased risk of suffering from psychological distress and depression because they usually take on a considerable part of extra care that their children need.This study was designed to determine prevalence and intensity of depression in mothers with a thalassemic child. Material and Methods: In this cross - sectional study, 65 mothers of children with thalassemia major (case group) and 65 mothers of children without thalassemia major (control group) were assessed using the Beck Depression Inventory (BDI). Data were analyzed by using SPSS (v 16.0) for windows. Results: Prevalence of depression was significantly higher in case group than that in control group (84.6%vs. 56.9%, p <0.05). Moderate depression had a highest prevalence in the both groups (33.4% in case group and 30.8% in control group). Prevalence of severe depression in case group was markedly higher than that in control group (29.2% vs. 3.1% p<0.05). There was a significant difference between intensity of depression in mothers of case group that had another child with beta-thalassemia major (p<0.05). Conclusion: Mothers of children with thalassemia major are vulnerable to depression. They need psychosocial support to promote their health. © Journal of Krishna Institute of Medical Sciences University

Comparative efficacy of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in Beta-Thalassemia patients

Background: Iron overload is a predictable and life-threatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The development of a safe and effective chelator has been the goal for many years. Aims and Objective: It was aimed to compare the effect of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in beta-thalassemia patients. Material and Methods: This controlled clinical trial was conducted on 46 major beta-thalassemic patients. Fifteen patients in deferiprone group received deferiprone 75mg/kg/day three times a day orally. Nineteen patients in deferoxamine group received deferoxamine 30-50 mg/kg/day subcutaneously for 8-12 hours/day and 5 days per week. Twelve patients in combined therapy group received deferiprone 75 mg/kg/day three times a day orally with deferoxamine 30–50 mg/kg subcutaneously every other day. Serum ferritin value was measured at the beginning and at the end of 6th and 12th months of study. Results: The mean of serum ferritin value in deferiprone group insignificantly increased from 2731± 1398.5 μg/L at the beginning to 2788.5 ± 978.6 μg/L and to 3331.8 ± 1833.9 μg/L at the end of 6th and 12th months of study, respectively. The mean of serum ferritin value in deferoxamine group insignificantly increased from 2883.5 ± 1598.1 μg/L at the beginning to 2935.3 ± 1258.2 μg/L at the end of 6th month of study and decreased to 2773.8 ± 1216.1 μg/L and 12th month of study. The mean of serum ferritin level in combined therapy group significantly decreased from 7498.7 ± 3512.9 μg/L at the beginning to 4839.9 ± 2698.2 μg/L (P < 0.001) and to 4298.2 ± 2288.7 μg/L (P < 0.001) at the end of 6th and 12th months of study, respectively. Conclusion: Combined therapy significantly decreases serum ferritin level. Study suggests deferiprone as a significant addition to support therapy in patients with betathalassemia major on regular transfusion regimens. © 2015 Journal of Krishna Institute of Medical Sciences University

Anti-tumor Activity of N4 [(E)-1-(2-hydroxyphenyl) Methylidene], N4-[(E)-2-Phenylethylidene], N4 [(E,2E)-3-Phenyl-2-propenylidene], and N4 [(E)ethylidene] Isonicotinohydrazide on K562 and Jurkat Cell Lines

Using the water eliminated mechanism, reactions of 4-pyridinecarboxylic acid hydrazide and salicylaldehyde, benzaldehyde, cinnamaldehyde, and formaldehyde afforded the corresponding N4[(E)-1-(2-hydroxyphenyl) methylidene] (NHPM), N4-[(E)-2-phenylethylidene] (NPI), N4[(E,2E)-3-phenyl-2-propenylidene] (NPPI), and N4[(E) ethylidene] (NEI) isonicotinohydrazide, in high yields, after several minutes, as reported. These new compounds have shown antitumor activity against two kinds of cancer cells, which are K562 (human chronic myeloid leukemia) and Jurkat (human T lymphocyte carcinoma)

Different treatment strategies for haemophilia a with Low inhibitor

Objective: To compare the cost-effectiveness of treatment options in three patients with haemophilia A and low titer inhibitors. Methodology: We used a longitudinal before-and-after design that was conducted in two phases assessed retrospectively: Phase I was 6 months preceding the introduction of recombinant activated factor VII (rFVIIa), during which patients received on-demand usual care with plasma derived factor VIII regimes, phase two was 6 month treatment on rFVIIa. We determined the clinical response and the cost of treatment with NovoSeven in three patients with low titer inhibitors to factors VIII compared with other treatment regime previously used in these patients (Plasma derived factor VIII). Results: Total number of bleeding episodes, re-treatments and need of hospitalization were 21, 11 and 12 in phase 1 vs. 19, 0 and 0 in phase two respectively. Total cost of rFVIIa and plasma derived factor VIII treatment was USD 98600 vs. USD 77000. Conclusion: rFVIIa is clinically effective. It resulted in 100 reduction in the number of re-treatments, hospitalization and 21.9 reduction in the total cost compared to treatment with plasma derived factor VIII regime

The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients

Objective: To determine the effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Method and materials: This controlled clinical trial was conducted on 26 major beta-thalassemic patients. Twelve patients in case group received deferiprone 75 mg/kg/day three times a day (TDS) orally with deferoxamine 30-50 mg/kg subcutaneously every other day. Fourteen patients in control group received deferoxamine 30-50 mg/kg/day subcutaneously for 6-12 hours/day and 5-6 days per week. Serum ferritin level was measured at the beginning and at the end of the third and the sixth months of study. Side effects of combined therapy were assessed. Data were analyzed by SPSS software v: 16.0 and t-Student and compared t-tests. Results: The mean of serum ferritin level in case group significantly decreased from 7539.8 ± 3434.9 μg/l at the beginning of study to 4848.7 ± 2706.2 μg/l (P < 0.001) and to 4338.3 ± 2308.8 μg/l (P < 0.001) at the end of the third and the sixth months of study, respectively. The mean of serum ferritin level in control group insignificantly increased from 5668 ± 3613.8 to 6210.8 ± 3940.9 μg/l and to 5742 ± 3205.9 μg/l at the end of the third and the sixth months of study, respectively. The common side effects of combined therapy were nausea (8.3) and arthropathy (8.3). A mild transient neutropenia and liver enzymes elevation happened in four patients of case group. Conclusion: Combined therapy with deferoxamine and deferiprone significantly decreases serum ferritin level. It has little side effect and is suggested for major beta-thalassemic patients as a suitable therapy. © W.S. Maney & Son Ltd 2012

Dissolution and precipitation kinetics of gamma prime in nickel base superalloy U-520

NRC publication: Ye

Linear friction welding of Titanium alloy

Peer reviewed: YesNRC publication: Ye

Determination of the Optimum Forging Conditions for a 7075 Aluminum Alloy

Peer reviewed: YesNRC publication: Ye